Chronic spontaneous urticaria treated with omalizumab: report of two cases
Background: Chronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms. Therapeutic options...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1551608 |
| _version_ | 1797683679674236928 |
|---|---|
| author | Giovanna Malara Claudio Sciarrone |
| author_facet | Giovanna Malara Claudio Sciarrone |
| author_sort | Giovanna Malara |
| collection | DOAJ |
| description | Background: Chronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms. Therapeutic options are limited; a number of drugs, recommended by international guidelines for the management of urticaria, lack regulatory approval for CSU and are prescribed off label. Omalizumab, a recombinant humanized anti IgE antibody, has recently received the approval for CSU treatment in Europe after an appropriate clinical development. Patients and results: Two case reports, that describes our encouraging experience with this therapeutic option in a real-life setting are discussed and deeply investigate the different scenario for the omalizumab use. Conclusion: In both cases, a complete remission of CSU symptoms after omalizumab treatment are demonstrated. Moreover, 6 months therapy gave the better results, whit a relapse, in one subject, 1 month after discontinuing omalizumab. Accordingly, a better understanding of long-term safety and efficacy should be needed to allow long-term administration in responding patients through a changing in prescription rules. |
| first_indexed | 2024-03-12T00:17:41Z |
| format | Article |
| id | doaj.art-1122a4af3e5a492799310345e1b42919 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:41Z |
| publishDate | 2018-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-1122a4af3e5a492799310345e1b429192023-09-15T14:08:34ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-12-012903510.1080/09546634.2018.15516081551608Chronic spontaneous urticaria treated with omalizumab: report of two casesGiovanna Malara0Claudio Sciarrone1Papardo HospitalPapardo HospitalBackground: Chronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms. Therapeutic options are limited; a number of drugs, recommended by international guidelines for the management of urticaria, lack regulatory approval for CSU and are prescribed off label. Omalizumab, a recombinant humanized anti IgE antibody, has recently received the approval for CSU treatment in Europe after an appropriate clinical development. Patients and results: Two case reports, that describes our encouraging experience with this therapeutic option in a real-life setting are discussed and deeply investigate the different scenario for the omalizumab use. Conclusion: In both cases, a complete remission of CSU symptoms after omalizumab treatment are demonstrated. Moreover, 6 months therapy gave the better results, whit a relapse, in one subject, 1 month after discontinuing omalizumab. Accordingly, a better understanding of long-term safety and efficacy should be needed to allow long-term administration in responding patients through a changing in prescription rules.http://dx.doi.org/10.1080/09546634.2018.1551608omalizumabchronic spontaneous urticariaige blocker |
| spellingShingle | Giovanna Malara Claudio Sciarrone Chronic spontaneous urticaria treated with omalizumab: report of two cases Journal of Dermatological Treatment omalizumab chronic spontaneous urticaria ige blocker |
| title | Chronic spontaneous urticaria treated with omalizumab: report of two cases |
| title_full | Chronic spontaneous urticaria treated with omalizumab: report of two cases |
| title_fullStr | Chronic spontaneous urticaria treated with omalizumab: report of two cases |
| title_full_unstemmed | Chronic spontaneous urticaria treated with omalizumab: report of two cases |
| title_short | Chronic spontaneous urticaria treated with omalizumab: report of two cases |
| title_sort | chronic spontaneous urticaria treated with omalizumab report of two cases |
| topic | omalizumab chronic spontaneous urticaria ige blocker |
| url | http://dx.doi.org/10.1080/09546634.2018.1551608 |
| work_keys_str_mv | AT giovannamalara chronicspontaneousurticariatreatedwithomalizumabreportoftwocases AT claudiosciarrone chronicspontaneousurticariatreatedwithomalizumabreportoftwocases |